Skip to main content
Premium Trial:

Request an Annual Quote

LJL BioSystems Markets Genotyping Technologies

Premium

SUNNYVALE, Calif.--LJL BioSystems has created a genomics science group within the company to apply its high-throughput screening technologies to the genotyping of single-nucleotide polymorphisms. The company said it has shipped its Analyst system for use in SNP analysis to several genomics customers already, including the Whitehead Institute for Genome Research and Exelixis Pharmaceuticals. The company also recently entered a collaboration with the University of California at Los Angeles in which it will apply what it calls HEFP technology for genotyping to SNPs identified by the university.

Lev Leytes, chairman and CEO of LJL, said, "Initial feedback from our customers who use our high-throughput systems for genomics applications indicates that the requirements of the genomics market are very similar to the emerging requirements of the drug discovery market that LJL is already addressing." He said those customers require both high-throughput and low cost-per-data point, "just like our high-throughput screening customers."

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.